CDNA shares climb after AlloHeme data show early AML/MDS relapse detection, backing its Transplant+ expansion into cell ...
A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...
The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
Yatiri Bio, a precision medicine company utilizing an AI-driven proteomic platform (ProteoCharts™) to identify therapeutically sensitive patient populations, reports results from a blinded ...
The AML Compliance Officer and accounting leadership should co-own key control interfaces. This includes data standards, reconciliation rules, escalation thresholds, and periodic control assurance ...
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...
Quantitative Risk Assessment in AML refers to a data-based approach that uses numerical scoring models to measure and score an entity’s exposure to Money laundering, Terrorist Financing, and ...
Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...
NEW YORK – Researchers in South Korea hope to shift ex vivo drug sensitivity testing for acute myeloid leukemia patients into the clinic, following data showing not only the feasibility of testing but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results